8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements

AMGEN filed an 8-K (Item 9.01) on Feb 3, 2026 attaching a press release as Exhibit 99.1 (dated Feb 3, 2026).

Filed with the SEC on February 3, 2026 · Summarized by InvestorsBot

AMGEN filed an 8-K (Item 9.01) on Feb 3, 2026 attaching a press release as Exhibit 99.1 (dated Feb 3, 2026). 📄 $AMGN #SECfiling #Amgen

The filing also includes Exhibit 104 — Cover Page Interactive Data File (Inline XBRL). 💾 $AMGN #XBRL #Investing

Report signed Feb 3, 2026 by Peter H. Griffith, EVP & CFO. Filing appears limited to exhibits (no other Item disclosures). ✍️ $AMGN #SEC #Pharma

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

AMGEN filed an underwriting agreement dated Feb 17, 2026 — BofA Securities, Citigroup, J.P.

8-K · February 19, 2026

BREAKING: $AMGN sold $4.0B of senior notes across 2031/2036/2046/2056 maturities — net proceeds ≈ $3.961B.

8-K · February 19, 2026

8-K · February 3, 2026

Amgen filed a Termination Agreement with Kyowa Kirin dated Jan 30, 2026 (Exhibit 10.1).

8-K · January 30, 2026

On Jan 30, 2026 Amgen ($AMGN) entered a Termination Agreement with Kyowa Kirin to end the June 1, 2021…

8-K · January 30, 2026